TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rein Therapeutics ( (RNTX) ) has shared an announcement.
Rein Therapeutics, Inc. has entered into a Pre-Paid Advance Agreement with YA II PN, Ltd., allowing the company to request pre-paid advances of up to $6.0 million over a 12-month period. On July 29, 2025, an initial advance of $1.0 million was made, followed by a second advance on September 8, 2025, both resulting in net proceeds of $0.95 million each. The agreement includes conditions such as an 8% interest rate on outstanding balances, with the possibility of increasing to 18% upon default, and allows Yorkville to convert outstanding balances into common stock.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 68,102
Technical Sentiment Signal: Sell
Current Market Cap: $31M
Learn more about RNTX stock on TipRanks’ Stock Analysis page.